20 Lung Cancer Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Lung Cancer Studies in San Francisco

NCT06627647Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatmen...

San Francisco, CAPHASE31,160 participantsAstraZeneca

View Study Details

NCT06692738Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

San Francisco, CAPHASE31,160 participantsAstraZeneca

View Study Details

NCT06561386Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squa...

San Francisco, CAPHASE31,000 participantsBristol-Myers Squibb

View Study Details

NCT06312137Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypo...

San Francisco, CAPHASE3780 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06623422Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

San Francisco, CAPHASE3680 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06917079Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumo...

San Francisco, CAPHASE1665 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06162221Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Stan...

San Francisco, CAPHASE1616 participantsRevolution Medicines, Inc.

View Study Details

NCT04410796Recruiting

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change...

San Francisco, CAPHASE2571 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05786924Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combin...

San Francisco, CAPHASE1554 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06203210Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

San Francisco, CAPHASE3540 participantsDaiichi Sankyo

View Study Details

NCT07185997Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) ...

San Francisco, CAPHASE3480 participantsArriVent BioPharma, Inc.

View Study Details

NCT04165070Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

San Francisco, CAPHASE1450 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06452277Recruiting

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutat...

San Francisco, CAPHASE3444 participantsBayer

View Study Details

NCT07195695Recruiting

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions ...

San Francisco, CAPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT07566052Recruiting

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If ...

San Francisco, CAPHASE3356 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06343402Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 ...

San Francisco, CAPHASE1350 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT05882058Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard tre...

San Francisco, CAPHASE2204 participantsBoehringer Ingelheim

View Study Details

NCT07491497Recruiting

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evalu...

San Francisco, CAPHASE1160 participantsTRIANA Biomedicines, Inc.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

San Francisco, CAPHASE1120 participantsSystImmune Inc.

View Study Details

NCT04302025Recruiting

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors tha...

San Francisco, CAPHASE299 participantsGenentech, Inc.

View Study Details

About Lung Cancer Clinical Trials in San Francisco

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 20 lung cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 10,789 participants. Research is being sponsored by AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme LLC and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in San Francisco — FAQ

Are there lung cancer clinical trials in San Francisco?

Yes, there are 20 lung cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 20 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated October 17, 2026 from ClinicalTrials.gov